MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1

Clinical and Experimental Medicine

Volumn 13, Issue 2, 2013, Pages 109-117

  Li, Laisheng ^a   Yuan, Linjin ^a   Luo, Jinmei ^b   Gao, Jie ^a   Guo, Jiaoli ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bcl 2; Breast cancer; miR 34a; SIRT1; Tumor suppressor

Indexed keywords

FLUOROURACIL; MICRORNA 34A; PROTEIN BCL 2; SIRTUIN 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIRTUIN 1;

EID: 84877768657     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0186-5     Document Type: Article

References (38)

1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215-233. doi: 10.1016/j.cell.2009.01.002
2. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857-866. doi: 10.1038/nrc1997
3. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559-1564. doi: 10.1126/science.1203543
4. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13(3):317-323. doi: 10.1038/ncb2173
5. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26(5):745-752. doi: 10.1016/j.molcel.2007.05.010
6. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM (2008) A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res MCR 6(5):735-742. doi: 10.1158/1541-7786.MCR-07-2102
7. Entschladen F, Drell TLt, Lang K, Joseph J, Zaenker KS (2004) Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5(4):254-258. doi: 10.1016/S1470-2045(04)01431-7
8. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A (2009) MicroRNA expression profiling of male breast cancer. Breast Cancer Res BCR 11(4):R58. doi: 10.1186/bcr2348
9. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92-105. doi: 10.1101/gr.082701.108
10. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G (2010) miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70(5):1793-1803. doi: 10.1158/0008-5472.CAN-09- 3112
11. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discovery 9(10):775-789. doi: 10.1038/nrd3179
12. Ghawanmeh T, Thunberg U, Castro J, Murray F, Laytragoon-Lewin N (2011) miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, Docetaxel or combination treatment. Oncology 81(5-6):330-335. doi: 10.1159/000334237
13. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A (2012) Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 72(2):460-471. doi: 10.1158/0008-5472.CAN-11- 1977
14. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17(2):193-199. doi: 10.1038/cdd.2009.56
15. Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30(43):4386-4398. doi: 10.1038/onc.2011.148
16. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070. doi: 10.1158/0008-5472.CAN-05-1783
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
18. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H (2011) ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9-mediated suppression of SOX2. Cancer Res 71(9):3410-3421. doi: 10.1158/0008-5472.CAN-10-3340
19. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4(7):e6146. doi: 10.1371/journal.pone.0006146
20. Kasinski AL, Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11(12):849-864. doi: 10.1038/nrc3166
21. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, Chun KH (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155(3):427-434. doi: 10.1016/j.jconrel.2011.06.026
22. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6(5):376-385. doi: 10.1038/nrm1644
23. Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, Boyd NF (2011) Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 103(12):942-950. doi: 10.1093/jnci/djr138
24. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501-1512. doi: 10.1002/pros.21185
25. Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39 (Database issue): D152-D157. doi: 10.1093/nar/gkq1027
26. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15-20. doi: 10.1016/j.cell.2004.12.035
27. Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69(16):6704-6712. doi: 10.1158/0008-5472. CAN-09-1298
28. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211-215. doi: 10.1038/nm.2284
29. Rivera E, Gomez H (2010) Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res BCR 12(Suppl 2):S2. doi: 10.1186/bcr2573
30. Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 11(10):735-748. doi: 10.1038/nrc3125
31. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, Thomas-Tikhonenko A (2011) Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 30(22):2587-2594. doi: 10.1038/onc.2010.634
32. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582(10):1564-1568. doi: 10.1016/j.febslet.2008.03.057
33. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN (1997) Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15(7):647-652. doi: 10.1038/nbt0797-647
34. Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, Cho YJ (2011) miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 13(2):165-175. doi: 10.1093/neuonc/noq179
35. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26(34):5017-5022. doi: 10.1038/sj.onc.1210293
36. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70(14):5923-5930. doi: 10.1158/0008-5472.CAN-10-0655
37. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Nat Acad Sci USA 105(36):13421-13426. doi: 10.1073/pnas.0801613105
38. Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, Secchiero P (2011) miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res Off J Am Assoc Cancer Res 17(9):2712-2724. doi: 10.1158/1078-0432.CCR-10-3244